Company Monitoring Page for Incyte

latest headlines for company on cafepharma

3 Biotech Stocks That Could Become M&A Targets
Motley Fool
Sat, 06/17/17 - 03:05 pm
Tags:
biotech, M&A, Mallinckrodt, Tesaro, Incyte
Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Endpoints
Mon, 06/5/17 - 10:08 am
Tags:
Incyte, ASCO 2017, epacadostat, non-small cell lung cancer, Keytruda
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
Tue, 05/30/17 - 11:48 am
Tags:
ASCO, IDO inhibitors, CAR-T, PDL-1 inhibitors, Merck, Incyte, NewLink Genetics, Novartis, Juno Therapeutics, Bristol-Myers Squibb
7 Areas to watch from the ASCO abstracts
BioPharma Dive
Fri, 05/19/17 - 11:35 am
Tags:
ASCO 2017, oncology, Incyte, Merck, Eli Lilly, CAR-T, NewLink Genetics, Amgen, Roche, Kite Pharma, Juno Therapeutics
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Endpoints
Thu, 05/18/17 - 12:08 am
Tags:
Incyte, epacadostat, ASCO 2017, Merck, Keytruda, non-small cell lung cancer
Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid
Endpoints
Tue, 04/18/17 - 09:42 am
Tags:
Incyte, Pharma CEOs, Hervé Hoppenot, executive pay
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
Mon, 04/17/17 - 11:32 am
Tags:
FDA, rheumatoid arthritis, Eli Lilly, Incyte, baricitinib
Biotech Movers: OncoMed, Incyte, Omeros
TheStreet.com
Mon, 04/17/17 - 11:22 am
Tags:
biotech, OncoMed, tarextumab, small cell lung cancer, Incyte, Eli Lilly, baricitinib, Omeros
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Marketwatch
Fri, 04/14/17 - 10:48 am
Tags:
Eli Lilly, Incyte, FDA, rheumatoid arthritis, baricitinib
Traders say mergers and acquisitions could bring boost to biotech stocks
CNBC
Fri, 04/14/17 - 10:00 am
Tags:
M&A, biotech, Tesaro, Incyte
We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble
Endpoints
Thu, 04/13/17 - 11:48 am
Tags:
Eli Lilly, FDA, baricitinib, drug pricing, Incyte
3 Big Drugmakers Most Likely to Buy Incyte
Motley Fool
Wed, 04/12/17 - 11:57 am
Tags:
Incyte, M&A, Gilead Sciences, Amgen, Bristol-Myers Squibb
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Tue, 04/11/17 - 10:07 am
Tags:
Incyte, epacadostat, olumiant, Jakafi, immuno-oncology
Would Gilead Sciences Make This Staggeringly Audacious Move?
Motley Fool
Sun, 04/9/17 - 12:27 pm
Tags:
Gilead Sciences, M&A, Celgene, Incyte
Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials
Fierce Pharma
Tue, 04/4/17 - 11:10 pm
Tags:
Merck, Bristol-Myers Squibb, Incyte, Keytruda, Opdivo, non-small cell lung cancer
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Tags:
Neurocrine, Incyte, Eli Lilly, Biomarin, Ingrezza, baricitinib, Brineura
Merck, Incyte Expand Cancer Collaboration
Barron's
Fri, 03/31/17 - 10:00 pm
Tags:
Merck, Incyte, epacadostat, Keytruda, melanoma
Gilead Sciences: Is an Incyte Deal ‘Reasonable’?
Barron's
Mon, 03/13/17 - 11:26 am
Tags:
Gilead Sciences, Incyte, M&A
Tapping into the rare disease market
BioPharma Dive
Fri, 03/10/17 - 09:00 pm
Tags:
Rare Diseases, Incyte, Horizon Pharma, Lundbeck
Incyte tops Street 4Q forecasts
Yahoo/AP
Tue, 02/14/17 - 12:09 pm
Tags:
Incyte, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.